Papillon’s PPL-002 awarded US orphan drug designation for Danon disease
Oct. 2, 2024
The FDA has awarded orphan drug designation to Papillon Therapeutics Inc.’s PPL-002, an experimental gene-modified CD34+ hematopoietic stem and progenitor cell (HSPC) therapy, for the treatment of Danon disease.